MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

Also called NCT07632157

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 196 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07632157
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07632157. Randomized; double masking; primary purpose treatment. Start 2026-11-10 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
Acronym
MAGNETIC-AF
Condition
Atrial Flutter With Rapid Ventricular Response
Intervention (Drug)
Magnesium Sulfate 2g
Intervention (Drug)
Magnesium Sulfate 4g
Intervention (Drug)
Saline (0.9% NaCl)
Lead sponsor
Wake Forest University Health Sciences (class: other)

Record details

Record id
cardio:ct-nct07632157
Content hash
d5b5336d1ade84172fb47abea628f26a32455501eb35b8bc0708bfcdee06933a